newsfilter
← Latest News
GlobeNewswire·

Small Pharma Announces Further Positive Data from SPL026 Phase IIa Trial in Major Depressive Disorder Strengthening Topline Efficacy Results

-Patients' self-reported depression and wellbeing scores corroborate MADRS efficacy data-Statistically significant improvement in anxiety symptoms offers potential in new indications beyond depression LONDON, March